Results 51 to 60 of about 405 (131)

Beta-Thalassemia: A Pharmacological Drug-Based Treatment

Drugs and Drug Candidates
This review was performed to determine the potential of drugs that can remove or decrease the requirements for blood transfusion among beta (β)-thalassemia patients.
Shrabonti Biswas, Shanita Zaman Smrity, Md. Shimul Bhuia, Fatema Akter Sonia, Mst. Asma Aktar, Raihan Chowdhury, Tawhida Islam, Muhammad Torequl Islam, Gabriel Gonçalves Alencar, Cicera Laura Roque Paulo, Ana Pavla Almeida Diniz Gurgel, Henrique Douglas Melo Coutinho   +11 more
doaj   +1 more source

Recent Advances in Thalassemia Management: From Curative Therapies to Artificial Intelligence

Thalassemia Reports
Thalassemia is an inherited hemoglobin disorder characterized by chronic hemolytic anemia and substantial long-term healthcare needs. In β-thalassemia major, patients typically require regular red blood cell transfusions with iron chelation to prevent ...
Mohamed Medhat Abdelwahab Gamaleldin, Shaimaa Mahmoud Nashat Sayed Abdelhalim, Ivo Abraham   +2 more
doaj   +1 more source

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +2 more sources

AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes

Haematologica, 2020
Pyruvate kinase (PK) deficiency is a rare hereditary disorder affecting red cell (RBC) glycolysis, causing changes in metabolism including a deficiency in ATP.
Minke A.E. Rab, Brigitte A. van Oirschot, Penelope A. Kosinski, Jeffrey Hixon, Kendall Johnson, Victor Chubukov, Lenny Dang, Gerard Pasterkamp, Stephanie van Straaten, Wouter W. van Solinge, Eduard J. van Beers, Charles Kung, Richard van Wijk   +12 more
doaj   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +2 more sources

Targeting pyruvate kinase M2 for the treatment of kidney disease

Frontiers in Pharmacology
Pyruvate kinase M2 (PKM2), a rate limiting enzyme in glycolysis, is a cellular regulator that has received extensive attention and regards as a metabolic regulator of cellular metabolism and energy.
Dan-Qian Chen, Jin Han, Jin Han, Hui Liu, Kai Feng, Ping Li   +5 more
doaj   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +2 more sources

Global research landscape and thematic transitions in pyruvate kinase deficiency: a decadal bibliometric analysis (2015–2025)

Frontiers in Medicine
BackgroundPyruvate kinase deficiency (PKD) is the most common cause of congenital non-spherocytic hemolytic anemia. This study systematically maps the scholarly output and evolving research trends in PKD over the past decade (2015–2025) to identify core ...
Wanyi Zhao, Yang Wang, Na Gao, Wenzheng Yu, Zengyan Liu   +4 more
doaj   +1 more source

Rare red cell enzymopathies in the Indian population: A comprehensive review

Pediatric Hematology Oncology Journal
Red blood cell enzyme deficiencies are a rare category of hemolytic anaemia that typically present in children with varying degrees of hemolysis, indirect hyperbilirubinemia and splenomegaly.
Prabhakar Kedar, Rashmi Dongerdiye, Ritika Khurana, Sangeeta Mudaliar   +3 more
doaj   +1 more source

SICKLE CELL DISEASE UPDATE: NEW TREATMENTS

Hematology, Transfusion and Cell Therapy
Sickle-cell disease is the most common genetic blood disorder, causing blockage of the circulation and resulting painful vaso-occlusive episodes, acute chest syndrome, stroke, chronic anemia, and multiorgan failure, with increased mortality.
Utku Aygüneş
doaj   +1 more source